Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Improved adeno-associated virus (AAV) serotype 1 and 5 vectors for gene therapy.

Scientific reports - 1 Jan 2013

Sen Dwaipayan, Balakrishnan Balaji, Gabriel Nishanth, Agrawal Prachi, Roshini Vaani, Samuel Rekha, Srivastava Alok, Jayandharan Giridhara R

Abstract excerpt

Despite significant advancements with recombinant AAV2 or AAV8 vectors for liver directed gene therapy in humans, it is well-recognized that host and vector-related immune challenges need to be overcome for long-term gene transfer. To overcome these limitations, alternate AAV serotypes (1-10) are being rigorously evaluated. AAV5 is the most divergent (55% similarity vs. other serotypes) and like AAV1 vector is...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Neutralizing
Share to Capsid Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dependovirus

Share to Genetic Therapy

Share to Serine

Share to Threonine

Share to Transduction, Genetic

Share to Ubiquitination

Source

Open in PubMed Open full text

Identifiers

PMID: 23665951
DOI: 10.1038/srep01832
PMCID: PMC3652085

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Improved adeno-associated virus (AAV) serotype 1 and 5 vectors for gene therapy.PMID 23665951Read ↗

Adeno-Associated Virus Gene Therapy for Liver DiseaseSemantic proximity Read ↗

The deLIVERed promises of gene therapy: Past, present, and future of liver-directed gene therapySemantic proximity Read ↗

Gene Therapy: Paving New Roads in the Treatment of HemophiliaSemantic proximity Read ↗

Directed Evolution of AAV Serotype 5 for Increased Hepatocyte Transduction and Retained Low Humoral SeroreactivitySemantic proximity Read ↗

Current and Emerging Issues in Adeno-Associated Virus Vector-Mediated Liver-Directed Gene TherapySemantic proximity Read ↗

Adeno-associated viral vectors for the treatment of hemophiliaSemantic proximity Read ↗

The intersection of vector biology, gene therapy, and hemophiliaSemantic proximity Read ↗

Development of Novel Adenoviral Vectors to Overcome Challenges Observed With HAdV-5–based ConstructsSemantic proximity Read ↗

Superior In vivo Transduction of Human Hepatocytes Using Engineered AAV3 CapsidSemantic proximity Read ↗

Rationale and strategies for the development of safe and effective optimized AAV vectors for human gene therapySemantic proximity Read ↗

Adeno-associated virus-based gene therapy for hemophilia–addressing the gapsSemantic proximity Read ↗

State of the art: gene therapy of haemophiliaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.